My blog from the intersection of patient & pharmacist
Articles about research in general and M.E. research, along with links to the short and easily digested monthly M.E. research round-ups I write as part of my work as Volunteer Pharmacist & Research Officer for Action for M.E.
Find out more about how and why we produce these round-ups here
Sign up to receive an email from me when a new research round-up is published here
Last month, New Scientist ran a feature on research findings of energy metabolism abnormalities in people with M.E. Although this is the same research published elsewhere, it’s great to see it in a mainstream science mag. Read the New Scientist article
Scientific overview of the drug research updates given at the International Association for CFS/ME 2016 conference, written by Cort Johnson.The drugs mentioned are rituximab, cyclophosphamide, desmopressin, low-dose naltrexone, rintatolimod (Ampligen), and some supplements. Heard through @firestormmer. Read Treating ME/CFS: The IACFS/ME Conference Overviews – Part V
There’s a big difference between us feeling like we have zero energy and that actually being the problem within our cells but the link between our symptoms and the underlying processes in M.E. is becoming clearer.Read More »
There’s a gaping chasm between what’s provided and what people with M.E. need. From where I’m sitting, as a patient first and health professional second, the only way to get what we need is to collaborate. In this blog I show the ways patients are becoming more involved in research and healthcare.Read More »
My summary for Action for M.E. of the research published online in Proceedings of the National Academy of Sciences of the United States of America, and reported in UK press, which looked closely at the blood chemistry in people with M.E. with a research technique called “metabolomics”. New research: distinct biological differences in M.E.
Today the UK government responded to a petition calling for more investment into M.E./CFS research. I’ve included a summary of the response, a run down of the current projects by the MRC to encourage more research, and links to research news.
The Royal Pharmaceutical Society’s professional publication, Pharmaceutical Journal, has run a feature on the rituximab trials and how these could be revealing the underlying mechanisms of the illness.
In March I interviewed Professor Davey Smith to find out what his specialism of epigenomics could bring to the UK CFS/M.E. Research Collaborative’s Grand Challenge and what this method of research could reveal about M.E.Read More »
The Association of the British Pharmaceutical Industry (ABPI) is calling for NICE to reform the way it assesses treatments for its guidelines, echoing the views I’ve read on social media from health professionals, academics and frustrated patients with long-term conditions such as M.E., fibromyalgia and vitamin B12 deficiency, amongst many others.Read More »
Today sees the launch of the online public engagement part of a review to find ways of speeding up access to innovative new drugs, devices and diagnostics for patients in the UK. The patient champion for the review urges patients and patient representatives to get involved. Read More »
There are two routes from discovery to licensing, depending on whether the drug is a completely new one (de novo pathway) or whether it is an existing drug discovered to be an effective treatment of a different symptom or condition (repositioning pathway). Read More »